Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Patent
1997-08-22
1998-12-01
Housel, James C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
4241931, 4241981, 4242031, 530403, 530813, 530825, A61K 3909
Patent
active
058434615
ABSTRACT:
This invention relates to antigenic conjugate molecules comprising the capsular polysaccharide of Group B streptococcus type II which are covalently linked to protein. This invention also relates to vaccines and methods of immunizing mammals, including humans against infection by Group B streptococcus type II (GBS II). Multivalent vaccines comprising the conjugate molecules of this invention and antigens to other pathogenic bacteria are also claimed.
REFERENCES:
patent: 4207414 (1980-06-01), Kasper
patent: 4284537 (1981-08-01), Beachley
patent: 4324887 (1982-04-01), Kasper
patent: 4356170 (1982-10-01), Jennings
patent: 4356263 (1982-10-01), Kasper
patent: 4367221 (1983-01-01), Kasper
patent: 4367222 (1983-01-01), Kasper
patent: 4425330 (1984-01-01), Norcross et al.
patent: 4619828 (1986-10-01), Gordon
patent: 4757134 (1988-07-01), Blake et al.
patent: 4789735 (1988-12-01), Frank et al.
patent: 4902506 (1990-02-01), Anderson et al.
patent: 5302386 (1994-04-01), Kasper
patent: 5367223 (1994-11-01), Kasper
Attachment A (Work Statement) from Request for Proposal No. NIH-NIAID-DMID-92-13, issued by the Department of Health and Human Services for the National Institutes of Health on Jan. 21, 1992, entitled, "Prevention of Group B Streptococcal Infections in Neonatal and Infant Populations".
Abstract of Grant No. 2R37A23339-08, "Immunochemistry of Group B streptococcus polysaccharides (human, mice, rabbits)", Kasper, D.L., Principal Investigator, Fed. Research in Progress, printout of Jan. 26, 1993 for fiscal year 1992.
Abstract of Grant No. 5R01AI30628-02, "Prevention of perinatal group B streptococcal infections (human, mice, rabbits)", Kasper D.L., Principal Investigator, Fed. Research in Progress, printout of Jan. 26, 1993 for fiscal year 1992.
Baker, C.J., "Immunization to Prevent Group B Streptococcal Disease: Victories and Vexations", Journal of Infectious Disease, vol. 161, No. 5, pp. 917-921, May 1990.
Bittle, J.L., et al. "Vaccines Produced by Conventional Means to Control Major Infectious Diseases of Man and Animals", Adv. Vet. Sci. Comp. Med., vol. 33, pp. 1-63, Feb. 1989.
Coleman, R.T., et al., "Prevention of Neonatal Group B Streptococcal Infections: Advances in Maternal Vaccine Development", Obst. Gynec., vol. 80, No. 2, pp. 301-309, Aug. 1992.
Dintzis, "Rational Design of Conjugate Vaccines", Pediatric Research, vol. 32, No. 4, pp. 376-385, Oct. 1992.
Feldman, et al. "The immune response to the group B streptococcus", Reviews in Medical Microbiology, vol. 3, No. 1, Jan. 1992, pp. 52-58.
Givner, et al. "Pooled Human IgH hyperimmune for type III Group B Streptococci: Evaluation against multiple strains in vitro and in experimental diseases", J. Infectious Diseases, vol. 163, pp. 1141-1145, May 1991.
Insel, R.A., "Maternal Immunization of Prevent Neonatal Infections", New England Journal of Medicine, vol. 319, No. 18, pp. 1219-1220, Nov. 1988.
Lerner, R.A., et al. "The Development of Synthetic Vaccines", The Biology of Immunologic Disease, Dixon, F.J., et al., eds., Sinauer Associates: Sunderland, MA, pp. 331-338, 1983.
Madoff, et al., "Maternal Immunization of Mice with Group B Streptococcal Type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple stereotypes", J. Clin. Invest., vol. 94, pp. 286-292, Jul. 1994.
Madoff, L.C., et al., "Protection of Neonatal Mice from Group B Streptococcal Infection by Maternal Immunization with Beta C Protein", Infect. Immun., vol. 60, No. 12, pp. 4989-4994, Dec. 1992.
Paoletti, L.C., et al. "Group B Streptococcus Type III Glycoconjugate Vaccines", Trends in Glycosci. Glycotech., vol. 4, No. 17, pp. 269-278, May 1992.
Paoletti, et al. "Immunogenicity of Group B Streptococcus Type III Polysaccharide-tetanus Vaccine in Baboons", Infection and Immunity, vol. 64, No. 2, pp. 677-679, Feb. 1996.
Wilkinson, H.W., et al. "Type-Specific Antigens of Group B Type Ic Streptococci", Infect. Immun., vol. 4, No. 5, pp. 596-604, Nov. 1971.
Ward et al, "Haemophilus influenzae Vaccines" in Vaccines Plotkin et al eds, W.B. Saunders Co. Philadelphia pp. 300-332, 1988.
Baker et al, Rev. Infec. Dis. 7(4):458-467, 1985.
Baker et al, New Eng. J. Med. 319(18): 1180-1185, 1988.
Boyer et al, Clin Res., 34(4) 962 A, 1986.
Wessels et al, Infect. Immun, 57(4):1089-1094, 1989.
Kasper et al, J. Clin Invest, 72:260-269, 1983.
Jenning et al, J. Biol. Chem. 258(3): 1793-1798, 1983.
Jennings et al, Biochemistry, 20(16): 4511-4518, 1981.
Sarvamangular et al, Proc. Natl Acad Sci, 88:7175-7179, 1991.
Heimas et al, The Opsomic Antibody Response of Female Rats to Type III Group B Streptococcal.
Immunization: a model for maternal Immunity, Vet. Immunol. Immunopath. 24:79-89, 1990.
Reuter et al, A Detailed Study of the Periodate Oxidation of Sialic Acids in Glycoproteins, Glycoconjugate J 6:35-44, 1989.
Facklam et al, "Streptococci and Aerococci" in Manual of Clinical Immunology, 4 ed. Lennette et al eds, American Society for Microbiology, 1985, pp. 154-175.
Wesseles et al, Immunogenicity in Animals of a Polysaccharide-Protein Conjugate Vaccine against Type III Group B Streptococcus; J. Clin. Invest 86:1428-1433, 1990.
Harold J. Jennings and C. Lugowski, "Immunochemistry of Groups A, B and C Meningococcal Polysaccharide Tetanus Toxoid Conjugates", The Journal of Immunology, 127:1011-1017 (1981).
Dick and Beurret (1989) "Glyconjugates of Bacterial Carobhydrafe Antigens--A Survey and Consideration of Designa dn Preparation Facts" Conjugate Vaccines) In Contrib. Microbiol. Immunol (Cruse, JM and Lewis, RE Tr. (eds.) Basel Karger vol. 10:48:114.
Jennings, (1983) "Capsular Polysaccharrides as Human Vaccines" In Advances Carobhydrate Chemistry and Biochemistry, vol. 41:155-207, Academic Press Inc. NY NY.
Paoletti (1992) Effects of Chain Length on the Immunogenicity in Rabbits of Group B Streptococcus Type III Oligosaccharride--Tetanus Toxoid Conjugate. J. Clin. Invest. 89:203-209.
Wessels, et al. (1989) "Isolation and Characterization of Type IV Group B Streptococcus Capsular Polysaccharide" Infection and Immunity, vol. 57, No. 4:1089-1094.
Kasper, et al. (1983) "Immunochemical Analysis and Immunogenicity of the Type II Group B Streptococcal Capsular Polysaccharide." J. Clin Invest, vol. 72:260-269.
Jennings, et al. (1982) "Structural Determination of the Capsular Polysaccharide Antigen of Type II Group B Streptococcus". The Journal of Biological Chemistry, vol. 258:1793-1798.
Paoletti, et al. (1990) An Oligosaccharide-Tetanus Toxoid Conjugate Vaccine against Type II Group B Streptococcus. The Journal of Biological Chemistry, vol. 265:18278-18283.
Rodewald, et al. (1992) "Neonatal Mouse Model of Group B Streptococcal Infection", The Journal of Infectious Diseases, vol. 166:635-9.
Paoletti (1992) "Group B Stretoccus Type II Polysaccharride--Tetanus Toxoid conjugate Vaccine" Infection and Immunity, vol. 60:4009-4014.
Jennings Harold J.
Kasper Dennis L.
Brigham and Women's Hospital, Inc.
Housel James C.
National Research Council of Canada
Shaver Jennifer
LandOfFree
Group B streptococcus type II polysaccharide-tetanus toxoid conj does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Group B streptococcus type II polysaccharide-tetanus toxoid conj, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Group B streptococcus type II polysaccharide-tetanus toxoid conj will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2393562